U. Herranz et al., Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers, INT J CL PH, 39(3), 2001, pp. 102-109
Citations number
18
Categorie Soggetti
Pharmacology & Toxicology
Journal title
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Objective: To assess the pharmacokinetic and pharmacodynamic interactions o
f emedastine difumarate, a new, antihistamine drug and ketoconazole. Materi
al: Twelve healthy Caucasian volunteers were administered emedastine difuma
rate 4 mg oral capsules once daily for 10 consecutive days. From day 6 to d
ay 10, ketoconazole 200 mg were co-administered twice daily. Methods: The e
ffects of multiple ketoconazole administration on emedastine kinetics were
evaluated by comparing values obtained for pharmacokinetic parameters at st
eady state, with and without ketoconazole. C-ss,C-max, C-ss,C-min, t(max),
AUC(ss), t(1/2) and Cl-ss/F values, obtained after both treatments, were co
mpared. Significant difference was defined as p < 0.05. QTc intervals from
ECGs at baseline, after emedastine treatment and after emedastine-ketoconaz
ole co-treatment were statistically compared. Results: Emedastine steady st
ate pharmacokinetics were slightly altered as a result of the ketoconazole
co-treatment. AUC(ss) rose by about 33% (increase ranging from 0.96 to 66.8
6, p < 0.001) and total clearance decreased by about 30% (ranging from 0.96
to 40.08, p < 0.001) with no change in the half-life. These events did not
lead to relevant pharmacodynamic changes, i.e. maximum prolongation of the
corrected QT interval (QTc) observed after 5 days co-treatment (day 10) wa
s of about 4%. Rate and severity of anti-H-1 sedation episodes also did not
increase on ketoconazole co-treatment. Conclusions: A moderate, but statis
tically significant interaction between emedastine and ketoconazole was obs
erved. Pharmacodynamic data indicate no increase in the QTc interval during
concomitant therapy. This result is consistent with the multiple emedastin
e metabolic pathways shown in man which supplement the metabolism by differ
ent enzymatic isoforms of CYP450. Concomitant treatment with emedastine and
ketoconazole in subjects with normal QT intervals can therefore, be undert
aken without special precautions.